Announcement • Jul 03
MedPal AI PLC has filed a Follow-on Equity Offering in the amount of £5 million. MedPal AI PLC has filed a Follow-on Equity Offering in the amount of £5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 142,857,133
Price\Range: £0.035
Transaction Features: Subsequent Direct Listing Announcement • Jun 18
MedPal AI Launches Juno Agentic AI Health Companion MedPal AI plc had announced the launch of "Juno", its next-generation agentic AI health companion, alongside a full upgrade of the technology that powers it. Juno represents a step change: from AI that answers when asked, to AI that works on the patient's behalf. Rather than waiting for a question, Juno proactively watches over a patient's health information through MedPal AI's New Health OS Portal and reaches out directly, by text over WhatsApp and the web. As part of the upgrade, MedPal AI has migrated its entire AI stack away from Google Vertex AI to a new multi-layer architecture. Anthropic's latest Claude models now drive Juno's agentic reasoning and conversation, while clinical response layers run on dedicated DigitalOcean infrastructure. The result is a faster, more capable and more autonomous health agent. The launch lands squarely in what the market has called the "OpenClaw moment": the shift, seen across consumer technology in 2026, to agentic assistants that understand natural text and voice and actively manage tasks for the user, rather than simply replying to prompts. Juno brings that same paradigm to healthcare. Consumer demand for AI-led health support has reached record levels. OpenAI reports that more than 40 million people now turn to ChatGPT every day with health-related questions. But general-purpose chatbots stop at information: they can describe a problem; they cannot resolve it. Juno is built to close that gap, and to close the loop. Trained by MedPal AI's own clinical services team, Juno provides advice and triage and, where clinically appropriate, connects the patient to one of MedPal AI's GPs, who can prescribe as appropriate. Medication is then dispensed through the Company's robotic dispensing infrastructure directly to the patient's door, with Juno following up to check on outcomes. The result is a single, continuous pathway from first question to resolved outcome. New Health does not just tell what the problem is, it helps to treat it. Announcement • Jun 12
Medpal Ai Announces Mhra Approval of First Oral Glp-1 for Weight Loss in Uk MedPal AI plc noted the announcement by the Medicines and Healthcare products Regulatory Agency (MHRA) granting UK marketing authorisation for the first oral GLP-1 receptor agonist tablet (oral semaglutide) for weight loss and weight management. The approval, granted to Novo Nordisk, makes the tablet available on a prescription-only basis to adults who are obese (BMI of 30 or above) or overweight (BMI of 27 to 30). The tablet is not currently available on the NHS and remains subject to evaluation by the National Institute for Health and Care Excellence (NICE), meaning private provision is presently the only route to access. The US launch of the same oral semaglutide product began in January 2026. According to Novo Nordisk's announcement of 7 June 2026, US prescriptions for the tablet surpassed three million in just over five months. Novo Nordisk reported that more than 80% of new pill prescriptions were for patients new to GLP-1 therapy, indicating that the oral formulation is expanding the treatable population rather than displacing existing injectable users. An orally administered option broadens the addressable market by reaching patients who are reluctant to self-inject and supports adherence and retention through a more convenient daily format. Because UK access is presently limited to the private channel pending NICE review, MedPal's vertically integrated model - AI-supported triage, human-in-the-loop clinical prescribing, and robotic dispensing - positions New Health to respond to anticipated patient demand. The timing of the approval is particularly significant for the Group, coinciding closely with the national launch of New Health. 
